Centre moves to reduce costs of trastuzumab deruxtecan, osimertinib & durvalumab, all 3 by British-Swedish pharma giant AstraZeneca. Doctors seek exemptions for more such drugs.
Likely to be presented to Cabinet before being tabled in Parliament, latest version of draft bill aims to regulate, restrict or ban online sale of prescription drugs.
In a statement, Biological E. said it plans to manufacture 75 million doses a month, anticipating more than 100 million doses per month by February 2022.
The vaccine Dengvaxia has to be administered to individuals aged 9 to 45, who have been infected with the dengue virus before and who live in areas where this infection is endemic.
The Modi govt must not damage India’s competitive advantage in vaccines & pharmaceuticals through absurd benchmarks that will not be trusted by other countries.
Drugs Controller General of India has granted 'conditional approval' to the vaccine candidates. A third candidate by Cadila Healthcare has got nod to conduct Phase III clinical trial.
DCGI issued a show-cause notice to Serum Institute following reports that human trials of the Oxford vaccine were paused in UK after a candidate had an adverse reaction.
The ministry wrote to DCGI, asking it to ascertain how many states, UTs have been covered and which of them are left, as far as the availability and distribution is concerned.
The chipmaker at the heart of the AI revolution may be the most influential stock in Wall Street history. Nvidia has been the primary driver of the market’s gains since the start of 2023.
ISRO’s LMV3 rocket set off the CMS-03 satellite from Sriharikota Sunday. It weighs 4,410 kg, will primarily serve Indian Navy and has a life of at least 15 years.
This world is being restructured and redrawn by one man, and what’s his power? It’s not his formidable military. It’s trade. With China, it turned on him.
COMMENTS